2019
DOI: 10.3390/cells8020153
|View full text |Cite
|
Sign up to set email alerts
|

Targeting the Hedgehog Pathway in Cancer: Current Evidence and Future Perspectives

Abstract: The Hedgehog pathway (HhP) plays an important role in normal embryonic development and its abnormal function has been linked to a variety of neoplasms. Recently, the complex mechanisms involved in this pathway have been deciphered and the cross talks with other important pathways involved in carcinogenesis have been characterized. This knowledge has led to the development of targeted therapies against key components of HhP, which culminated in the approval of vismodegib for the treatment of advanced basal cell… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

0
46
0
1

Year Published

2019
2019
2024
2024

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 46 publications
(47 citation statements)
references
References 151 publications
(147 reference statements)
0
46
0
1
Order By: Relevance
“…There were already existing clinically successful approaches of cancer therapies targeting at hedgehog signalling, such as some small molecules that can eliminate the activity of SMO, named SMO inhibitors. SMO antagonists showed potent therapeutic efficacy typically in skin and brain cancer patients .…”
Section: Discussionmentioning
confidence: 99%
“…There were already existing clinically successful approaches of cancer therapies targeting at hedgehog signalling, such as some small molecules that can eliminate the activity of SMO, named SMO inhibitors. SMO antagonists showed potent therapeutic efficacy typically in skin and brain cancer patients .…”
Section: Discussionmentioning
confidence: 99%
“…Vismodegib, an oral sonic hedgehog signaling pathway inhibitor, has recently been approved by the Food and Drug Association for the treatment of locally advanced, metastatic, and recurrent basal cell carcinomas that are ineligible for surgery or radiotherapy [4]. Several studies have demonstrated the efficacy and safety of this small molecule which selectively connects to the Smoothened protein and blocks intracellular signaling, deactivating the hedgehog pathway and thus inhibiting tumor growth [7]. As reported in our results, muscle spasms, dysgeusia, weight loss, and alopecia are the most frequently described adverse events associated with vismodegib therapy.…”
Section: Discussionmentioning
confidence: 99%
“…Hedgehog pathway signaling activates the glioblastoma Gli1/2/3 genes (named so because they were initially identified in glioblastomas [478]) through a complex epistatic pathway of negative regulators [479]. Targeting of the hedgehog pathway in cancer cells has been an efficient way to inhibit tumor growth [480][481][482][483].…”
Section: Classificationmentioning
confidence: 99%